CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 133 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,115,060 | -19.7% | 180,929 | -7.7% | 0.00% | 0.0% |
| Q2 2023 | $2,634,616 | -63.0% | 196,028 | -54.3% | 0.00% | -70.0% |
| Q1 2023 | $7,117,844 | +39.9% | 429,303 | +56.9% | 0.01% | +25.0% |
| Q4 2022 | $5,087,807 | -99.9% | 273,538 | -3.0% | 0.01% | +33.3% |
| Q3 2022 | $3,618,278,000 | +1574.4% | 282,017 | +814.9% | 0.01% | – |
| Q2 2022 | $216,090,000 | -2.9% | 30,826 | +14.8% | 0.00% | – |
| Q1 2022 | $222,653,000 | -39.1% | 26,858 | -50.3% | 0.00% | -100.0% |
| Q4 2021 | $365,587,000 | +167.0% | 54,001 | +109.0% | 0.00% | – |
| Q3 2021 | $136,936,000 | +64.9% | 25,837 | +78.9% | 0.00% | – |
| Q2 2021 | $83,064,000 | -39.0% | 14,446 | -51.1% | 0.00% | – |
| Q1 2021 | $136,207,000 | +152.7% | 29,546 | +83.1% | 0.00% | – |
| Q4 2020 | $53,908,000 | -29.5% | 16,140 | -37.3% | 0.00% | – |
| Q3 2020 | $76,415,000 | -11.9% | 25,729 | +37.0% | 0.00% | – |
| Q2 2020 | $86,777,000 | -72.3% | 18,783 | -76.9% | 0.00% | -100.0% |
| Q1 2020 | $313,417,000 | +632.7% | 81,407 | +613.7% | 0.00% | – |
| Q4 2019 | $42,776,000 | -47.3% | 11,407 | -25.4% | 0.00% | – |
| Q3 2019 | $81,211,000 | +85.5% | 15,294 | +34.2% | 0.00% | – |
| Q2 2019 | $43,768,000 | -57.2% | 11,398 | -43.1% | 0.00% | – |
| Q1 2019 | $102,214,000 | +764.5% | 20,042 | +540.7% | 0.00% | – |
| Q3 2018 | $11,824,000 | +21.2% | 3,128 | 0.0% | 0.00% | – |
| Q2 2018 | $9,759,000 | -76.8% | 3,128 | -82.2% | 0.00% | – |
| Q1 2018 | $42,107,000 | -27.5% | 17,618 | +18.6% | 0.00% | – |
| Q4 2017 | $58,091,000 | +230.2% | 14,857 | +112.8% | 0.00% | – |
| Q3 2017 | $17,592,000 | -15.0% | 6,981 | -6.9% | 0.00% | – |
| Q2 2017 | $20,694,000 | -44.5% | 7,498 | -50.7% | 0.00% | – |
| Q4 2015 | $37,254,000 | -18.5% | 15,206 | -0.2% | 0.00% | – |
| Q3 2015 | $45,687,000 | +76.5% | 15,229 | +143.0% | 0.00% | – |
| Q2 2015 | $25,883,000 | – | 6,267 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,378,584 | $3,116,000 | 2.30% |
| TANAKA CAPITAL MANAGEMENT INC | 147,993 | $298,000 | 0.90% |
| SOPHROSYNE CAPITAL LLC | 282,500 | $638,000 | 0.56% |
| Ghost Tree Capital, LLC | 200,000 | $452,000 | 0.27% |
| Orbimed Advisors | 1,895,000 | $4,283,000 | 0.05% |
| Financial Architects, Inc | 30,000 | $68,000 | 0.04% |
| Cowen Prime Services LLC | 43,550 | $98,000 | 0.04% |
| Rotella Capital Management, Inc. | 12,300 | $28,000 | 0.03% |
| FEDERATED HERMES, INC. | 3,267,000 | $7,384,000 | 0.02% |
| Baker Brothers Advisors | 569,853 | $1,288,000 | 0.02% |